Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan.
Company profile
Ticker
SYK
Exchange
Website
CEO
Kevin Lobo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
2Hip Holdings SAS • Aimago SA • Alcott Indemnity Company • Arrinex, Inc. • Berchtold + Fritz GmbH • Berchtold Corporation • Berchtold GmbH & Co. KG • Berchtold Holding Switzerland GmbH • BioMimetic Therapeutics USA, Inc. • BioMimetic Therapeutics, LLC ...
IRS number
381239739
SYK stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEF 14A
Definitive proxy
26 Mar 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Stryker Reports 2023 Operating Results and 2024 Outlook
30 Jan 24
CERT
Certification of approval for exchange listing
12 Dec 23
8-A12B
Registration of securities on exchange
11 Dec 23
8-K
Entry into a Material Definitive Agreement
11 Dec 23
8-K
Entry into a Material Definitive Agreement
8 Dec 23
424B5
Prospectus supplement for primary offering
8 Dec 23
424B5
Prospectus supplement for primary offering
7 Dec 23
Transcripts
SYK
Earnings call transcript
2023 Q4
30 Jan 24
SYK
Earnings call transcript
2023 Q3
2 Nov 23
SYK
Earnings call transcript
2023 Q2
3 Aug 23
SYK
Earnings call transcript
2023 Q1
1 May 23
SYK
Earnings call transcript
2023 Q1
1 May 23
SYK
Earnings call transcript
2022 Q4
31 Jan 23
SYK
Earnings call transcript
2022 Q3
1 Nov 22
SYK
Earnings call transcript
2022 Q2
27 Jul 22
SYK
Earnings call transcript
2022 Q1
29 Apr 22
SYK
Earnings call transcript
2021 Q4
28 Jan 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
76.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1734 |
Opened positions | 155 |
Closed positions | 136 |
Increased positions | 661 |
Reduced positions | 593 |
13F shares | Current |
---|---|
Total value | 79.06 tn |
Total shares | 289.52 mm |
Total puts | 1.13 mm |
Total calls | 1.52 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 30.67 mm | $8.38 tn |
BLK Blackrock | 26.08 mm | $7.13 tn |
Greenleaf Trust | 19.33 mm | $5.28 tn |
STT State Street | 14.00 mm | $3.84 tn |
Wellington Management | 13.66 mm | $3.73 tn |
T. Rowe Price | 11.90 mm | $3.25 tn |
Capital Research Global Investors | 10.34 mm | $2.82 tn |
Geode Capital Management | 6.26 mm | $1.71 tn |
BK Bank Of New York Mellon | 6.24 mm | $1.71 tn |
FMR | 5.97 mm | $1.63 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Spencer S Stiles | Common Stock | Payment of exercise | Dispose F | No | No | 353.19 | 3,796 | 1.34 mm | 51,806 |
21 Mar 24 | Spencer S Stiles | Common Stock | Option exercise | Acquire M | No | No | 0 | 203 | 0.00 | 55,602 |
21 Mar 24 | Spencer S Stiles | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 203 | 0.00 | 0 |
21 Mar 24 | James Andrew Pierce | Common Stock | Payment of exercise | Dispose F | No | No | 353.19 | 4,412 | 1.56 mm | 56,252 |
21 Mar 24 | James Andrew Pierce | Common Stock | Option exercise | Acquire M | No | No | 0 | 203 | 0.00 | 60,664 |
21 Mar 24 | James Andrew Pierce | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 203 | 0.00 | 0 |
21 Mar 24 | Menon Viju | Common Stock | Payment of exercise | Dispose F | No | No | 353.19 | 3,444 | 1.22 mm | 10,318 |
21 Mar 24 | Menon Viju | Common Stock | Option exercise | Acquire M | No | No | 0 | 158 | 0.00 | 13,762 |
21 Mar 24 | Menon Viju | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 158 | 0.00 | 0 |
21 Mar 24 | Lobo Kevin | Common Stock | Payment of exercise | Dispose F | No | No | 353.19 | 19,785 | 6.99 mm | 99,934 |
News
Stryker Unusual Options Activity For April 19
19 Apr 24
Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years
17 Apr 24
RBC Capital Maintains Outperform on Stryker, Raises Price Target to $386
15 Apr 24
TD Cowen Maintains Buy on Stryker, Raises Price Target to $400
11 Apr 24
Boston Scientific (BSX) Faces Rising Costs, Competition
11 Apr 24
Press releases
Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales
4 Apr 24
Stryker to announce financial results for its first quarter of fiscal year 2024
1 Apr 24
Stryker announces Annual Meeting of Shareholders
26 Mar 24
Stryker completes acquisition of SERF SAS
21 Mar 24
Monogram Orthopaedics (NASDAQ: MGRM) Aims To Overcome Robot Shortcomings With Its Advanced Solution
19 Mar 24